IL23R in the Swedish, Finnish, Hungarian and Italian populations: association with IBD and psoriasis, and linkage to celiac disease

Elisabet Einarsdottir1,2, Lotta LE Koskinen1,2, Emma Dukes1,2, Kati Kainu3, Sari Suomela3, Maarit Lappalainen2,4, Fabiana Ziberna5, Ilma R Korponay-Szabo6, Kalle Kurppa7, Katri Kaukinen8, Róza Ádány9, Zsuzsa Pocsai9, György Széles10, Martti Färkkilä11, Ulla Turunen12, Leena Halme13, Paulina Paavola-Sakki4,12, Tarcisio Not5, Serena Vatta5, Alessandro Ventura5, Robert Löfberg14, Leif Torkvist15, Francesca Bresso14, Jonas Halfvarson16, Markku Mäki7, Kimmo Kontula3,4, Ulpu Saarialho-Kere3, Juha Kere1,17, Mauro D'Amato17 and Päivi Saavalainen*†1,2

Address: 1Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland, 2Research Program for Molecular Medicine, Biomedicum Helsinki, Finland, 3Department of Dermatology, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland, 4Department of Medicine, University of Helsinki, Helsinki, Finland, 5Department of Reproductive and Development Sciences, University of Trieste and IRCCS “Burlo Garofolo” Children Hospital, Trieste, Italy, 6Heim Pal Children’s Hospital, Budapest and University of Debrecen, Budapest, Hungary, 7Paediatric Research Centre, University of Tampere Medical School and Tampere University Hospital, Tampere, Finland, 8Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital and Medical School, University of Tampere, Tampere, Finland, 9Faculty of Public Health, Department of Preventive Medicine, University of Debrecen, Debrecen, Hungary, 10Faculty of Public Health, Department of Epidemiology and Biostatistics, University of Debrecen, Debrecen, Hungary, 11Department of Surgery, Helsinki University Central Hospital, Helsinki, Finland, 12Department of Gastroenterology, Helsinki University Hospital, Helsinki, Finland, 13Department of Transplantation and Liver Surgery, University of Tampere Medical School, Tampere, Finland, 14Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 15Department of Surgery, Karolinska Institutet, Stockholm, Sweden, 16Department of Internal Medicine, Orebro University Hospital, Orebro, Sweden and 17Karolinska Institutet, Department of Biosciences and Nutrition, Clinical Research Centre, Huddinge, Sweden

Email: Elisabet Einarsdottir - elisabet.einarsdottir@helsinki.fi; Lotta LE Koskinen - lotta.koskinen@helsinki.fi; Emma Dukes - emmadukes@gmail.com; Kati Kainu - kati.kainu@helsinki.fi; Sari Suomela - sari.suomela@helsinki.fi; Maarit Lappalainen - maarit.lappalainen@helsinki.fi; Fabiana Ziberna - fabyz1@yahoo.it; Ilma R Korponay-Szabo - ilma.korponayszabo@uta.fi; Kalle Kurppa - kalle.kurppa@uta.fi; Katri Kaukinen - Katri.Kaukinen@uta.fi; Róza Ádány - adany@dote.hu; Zsuzsa Pocsai - pocsai@jaguar.unideb.hu; Martti Färkkilä - Martti.Farkkila@hus.fi; Ulla Turunen - Ulla.Turunen@hus.fi; Leena Halme - leena.halme@hus.fi; Paulina Paavola-Sakki - Paulina.Paavola-Sakki@hus.fi; Tarcisio Not - not@burlo.trieste.it; Serena Vatta - vatta@burlo.trieste.it; Alessandro Ventura - Ventura@burlo.trieste.it; Robert Löfberg - roblof@ki.se; Leif Torkvist - leif.torkvist@ki.se; Francesca Bresso - Francesca.bresso@mtc.ki.se; Jonas Halfvarson - Jonas.halfvarson@orebroll.se; Markku Mäki - markku.maki@uta.fi; Kimmo Kontula - Kimmo.Kontula@hus.fi; Ulpu Saarialho-Kere - Ulpu.Saarialho-Kere@helsinki.fi; Juha Kere - juha.kere@biosci.ki.se; Mauro D'Amato - Mauro.Damato@ki.se; Päivi Saavalainen* - paivi.saavalainen@helsinki.fi

* Corresponding author †Equal contributors

Abstract

Background: Association of the interleukin-23 receptor (IL23R) with inflammatory bowel disease (IBD) has been confirmed in several populations. IL23R also associates with psoriasis, suggesting that the gene may be an important candidate for many chronic inflammatory diseases.
Methods: We studied association of single-nucleotide variants in IL23R with IBD in Swedish patients, in both Crohn’s disease (CD) and ulcerative colitis (UC) subsets. The same genetic variants were also studied in Finnish patients with psoriasis or celiac disease, and in Hungarian and Italian patients with celiac disease.

Results: Association of IL23R with IBD was replicated in our Swedish patients, and linkage and association of the IL23R region with psoriasis was found in the Finnish population. The IL23R region was also linked to celiac disease in Finnish families, but no association of IL23R variants with celiac disease was found in the Finnish, Hungarian or Italian samples.

Conclusion: Our study is the first to demonstrate association of IL23R with CD and UC in Swedish patients with IBD. It is also the first study to report linkage and association of the IL23R region with psoriasis in the Finnish population. Importantly, this is the first report of linkage of the IL23R region to celiac disease, a chronic inflammatory condition in which IL23R has not been previously implicated.

Background
Association of genetic markers in the interleukin-23 receptor (IL23R) gene, and the intergenic region between IL23R and IL12RB2, with inflammatory bowel disease (IBD) was first identified in 2006 [1]. This association has since been replicated in both Crohn’s disease (CD) and ulcerative colitis (UC) [2-10], which are the two most frequent types of IBD, and also in paediatric CD [11-13], psoriasis [14-17] and ankylosing spondylitis [18]. However, no association of IL23R with CD could be found in the Japanese population [19]. IL23R does not appear to be associated with systemic lupus erythematosus [20], rheumatoid arthritis [21,22] or systemic sclerosis [23].

Our study set out to test the reported association of IL23R with IBD and psoriasis, using Swedish and Finnish patient materials. Given the chronic inflammatory nature of both conditions, as well as the tissue targeted by the immune response, we hypothesised that these same SNPs in the IL23R region might also play a role in celiac disease—a chronic inflammatory enteropathy caused by exposure to dietary gluten that can also manifest as a blistering cutaneous disease [24]. Association of IL23R with celiac disease was studied in three populations (Finnish, Italian and Hungarian) due to heterogeneous allele and/or haplotype frequencies in different population groups, where a functional variant may explain a significant part of disease risk in one population but not another.

Methods
Subject materials
Inflammatory bowel disease
Diagnosis of IBD (CD or UC) was assessed according to established clinical criteria, including endoscopic, radiology and histopathology data. The dataset consisted of 280 controls and 803 cases, of which 455 were UC cases and 348 were patients with CD. All patients were recruited at the Karolinska University Hospital in Stockholm; controls consisted of a random sample of ethnically-matched unselected individuals.

Celiac disease
The material consisted of 3 population datasets. From Finland, 260 families with celiac disease (185 multiplex families, 75 trios) and 165 single cases were collected at the University of Tampere. In most patients, celiac disease was diagnosed according to ESPGHAN criteria [25]. However, in a small number of cases, diagnosis was based only on the presence of disease-specific anti-endomysial antibodies (ca. 1% of cases). The 292 Finnish controls have been previously described [26]. The Hungarian dataset consisted of 400 families (204 multiplex families, 196 trios), 270 cases and 270 controls; they have been previously described [27]. The Italian dataset consisted of 139 cases and 198 controls. Untreated celiac patients were diagnosed in accordance with ESPGHAN criteria [25] and intestinal biopsies were analysed using Oberhuber’s classification [28]. A subset of Finnish (10%) and Hungarian (12%) cases were also afflicted with dermatitis herpetiformis (DH), the blistering cutaneous manifestation of celiac disease [29]. Given that the genetic risk factors underlying the gut and skin pathologies of celiac disease are speculated to be distinct [27], linkage analyses were performed on the total patient cohort as well as stratifying the Finnish and Hungarian pedigrees by the presence or absence of DH. Information regarding DH was not available for Italian patients with celiac disease or for a minor subset of the Finnish families (27 families).

Psoriasis
The dataset consisted of 255 Finnish families (64 multiplex families, 191 trios), including 385 affected individuals, and has been described previously [30]. One psoriasis patient from each family was randomly chosen and analysed against the Finnish control material described previously [26].
Table 1 gives a summary of all sample datasets in this study. Written informed consent was obtained from all participants in this study and local ethics committees approved the study protocols.

**Genotyping and analysis**

Power calculations were performed using the online Genetic Power Calculator [31], with power estimated to replicate the results of Duerr *et al.* (2006) [1] in our TDT and case-control materials. The prevalence of IBD was set as 0.001, celiac disease set as 0.01 and psoriasis set as 0.02. The frequency of the rare protective allele was set as 0.07; the OR was set as 0.50 (and not 0.26 as in [1] because this risk effect is likely to be inflated).

SNP markers in the *IL23R* region were chosen from Duerr *et al.* (2006) [1] and were typed by MALDI-TOF analysis on the Massarray Analyzer platform (Sequenom, San Diego, USA). All genotyping was performed at the MAF core facility in Karolinska Institute, Stockholm, Sweden. Markers rs7517847 and rs1495965 were not typed due to technical difficulties. Genotyping results, pedigree structure and affection status were imported into a BC|GENE LIMS database (Biocomputing Platforms, Espoo, Finland).

Deviations from Mendelian inheritance in the family materials were determined with PEDCHECK 1.1 [32] and marker genotypes were discarded in families where Mendelian inheritance errors were detected. Mendelian inheritance error-rates for the pedigrees with celiac disease were 0.18% for the Finnish dataset and 0.15% for Hungarian; the error-rate for the Finnish pedigrees with psoriasis was 0.25%. Genotyping success rates and conformity to Hardy-Weinberg equilibrium (HWE) are shown in Additional file 1.

MERLIN 1.0.1 [33] was used to perform non-parametric linkage analysis in the Finnish and Hungarian pedigrees with celiac disease, as well as the Finnish pedigrees with psoriasis. The – pairs and – exp functions were used. Haploview 4.0 [34] was used to study linkage disequilibrium (LD) patterns, estimate haplotypes and perform association analysis. Odds ratios (OR) were calculated and two-sided p-values reported. Genehunter (version 2.1 r5 beta) [35] was used to perform transmission-disequilibrium tests (TDT) in the family materials. To extract information about association from the family materials without the presence of linkage, we utilised a script that randomly selected one affected individual from each family to be used as cases in a case-control type analysis (Biocomputing Platforms, Espoo, Finland).

The Cochran-Mantel-Haenszel (CMH) function in PLINK [36] was used to perform a meta-analysis of the three celiac disease datasets. The Breslow-Day test, estimating

| Disease | Sample set | Sample size |
|---------|------------|-------------|
| IBD     | Swedish case-controls | UC cases 455, CD cases 348, Controls 280 |
| Celiac disease | Finnish families 260 families (185 multiplex, 75 trios) | Affected 607, Unaffected 379 |
|         | Finnish case-controls | Cases 165 |
|         | Hungarian families 400 families (204 multiplex, 196 trios) | Affected 606, Unaffected 474 |
|         | Hungarian case-controls | Cases 270, Controls 270 |
|         | Italian case-controls | Cases 139, Controls 198 |
| Psoriasis | Finnish families 255 families (64 multiplex, 191 trios) | Affected 385, Unaffected 516 |
| Controls | Finnish controls (from Lappalainen *et al.* 2008) | Controls 292 |

Datasets in this study. Multiplex families have more than one affected individual, trio families are comprised of father, mother, and an affected child. IBD indicates inflammatory bowel disease, UC indicates ulcerative colitis, and CD indicates Crohn’s disease.
Table 2: Single-marker association of *IL23R* to IBD, celiac disease and psoriasis

| rs   | N (cases/controls) | p-value | OR  | p-value | OR  | p-value | OR  | p-value | OR  | p-value | OR  | p-value | OR  |
|------|--------------------|---------|-----|---------|-----|---------|-----|---------|-----|---------|-----|---------|-----|
| rs100481 | 9*T     | 0.004    | 1.38| 0.006   | 0.76| 0.054   | 0.42| 0.002   | 0.45| 0.014   | 1.30| 0.088   | 0.130 |
| rs104896 | 29*C    | 0.013    | 1.36| 0.002   | 0.72| 0.044   | 1.27| 0.003   | 0.43| 0.012   | 1.34| 0.059   | 0.111 |
| rs220184 | 1*C     | 0.006    | 1.43| 0.049   | 0.80| 0.188   | 0.47| 0.022   | 0.51| 0.039   | 1.29| 0.323   | 0.312 |
| rs114658 | 04*G    | 0.273    | 0.665| 0.444  | 0.220| 0.390   | 0.492| 0.335   | 0.546|
| rs112090 | 26*A    | 0.803    | 0.324| 0.390   | 0.753| 0.778   | 0.570| 0.334   | 0.491|
| rs134315 | 1*C     | 0.524    | 0.865| 0.846   | 0.279| 0.677   | 0.399| 0.849   | 0.424|
| rs108896 | 77*A    | 0.853    | 0.203| 0.619   | 0.186| 0.357   | 0.776| 0.808   | 0.582|

Association of SNPs in *IL23R* to inflammatory bowel disease (IBD), psoriasis (PSOR) and celiac disease (CEL) in cohorts from Sweden (SWE), Finland (FIN), Hungary (HUN) and Italy (ITA). Association to ulcerative colitis [UC] and Crohn's disease [CD] in the Swedish IBD (A); to celiac disease in the Finnish, Hungarian and Italian populations or combined material (B); and to psoriasis in the Finnish population (C). OR refers to odds ratios. Statistically significant p-values (p < 0.05) are highlighted in bold; p-values lower than 10⁻³ are highlighted in bold and underlined. Detailed data are shown in Additional file 3.
homogeneity of odds ratios, was non-significant ($p > 0.05$).

**Results**

Additional file 2 shows the linkage disequilibrium (LD) patterns for the region surrounding $\text{IL23R}$ and $\text{IL12RB2}$ in the HapMap dataset. The position of the single-nucleotide polymorphisms (SNPs) analysed in this study is also shown.

**IL23R and inflammatory bowel disease**

The power of the IBD case-control dataset to replicate the findings of Duerr *et al.* (2006) was approximately 89%. The association of individual *IL23R* markers with IBD (UC, CD or both) is shown in Table 2A, with more detail in Additional file 3. The strongest associations were observed for SNPs rs11465804*G with the combined IBD dataset (CD and UC cases; $p = 0.002$, OR 0.42) and rs10489629*C with the UC cohort only ($p = 0.002$, OR 0.72).

Association of *IL23R* haplotypes with IBD is shown in Additional file 4. The haplotype TTCTGCAA was associated with risk of IBD in Swedish patients ($p = 0.009$, OR 1.38), while the CCTGATCG haplotype was associated with protection against IBD ($p = 0.001$, OR 0.41). It was not informative to calculate genotype association for rs11465804 or rs11209026 or the protective CCTGATCG haplotype because there were too few homozygotes for the rare protective allele.

**IL23R and celiac disease**

The power of the TDT analysis to replicate the results of Duerr *et al.* (2006) [1] was approximately 64% in the Finnish and 82% in the Hungarian families with celiac disease. The power in the Finnish and Hungarian case-control datasets was estimated at 80% and 90%, respectively; it was 44% for the Italian case-control dataset.

The Finnish pedigrees with celiac disease demonstrated linkage to the *IL23R* region (max lod = 3.24, $p = 0.00006$, 135 informative families; Table 3A) as well as significant over-transmission of the rs10489629-rs201841-rs11465804-rs11209026 TTTG haplotype in presence of linkage (data not shown; 74 transmissions, 44 non-transmissions, $p = 0.0005$). When TDT without linkage was performed, this haplotype was not significantly over-transmitted to cases (40 transmissions, 31 non-transmissions; $p = 0.28$). The TTTG haplotype matches with the risk-associated alleles reported by Duerr *et al.* (2006) [1], with the exception of the T allele of rs2201841. The Hungarian pedigrees with celiac disease showed neither significant linkage to the SNPs in the *IL23R* region (lod = 0.4, $p$

---

**Table 3: Linkage to *IL23R***

|          | Samples                  | max Z-value | max lod | max lod p-value |
|----------|--------------------------|-------------|---------|-----------------|
| **A**    | **Celiac disease**       |             |         |                 |
|          | Finnish families (135)   | 3.19        | 3.24    | 0.00006         |
|          | Hungarian families (132) | 1.25        | 0.4     | 0.08            |
|          | Finnish and Hungarian families (268) | 3.22 | 3.04 | 0.00009         |
| **B**    | **Celiac disease-DH vs. non-DH** |            |         |                 |
|          | Finnish DH (34)          | 1.87        | 1.03    | 0.015           |
|          | Finnish non-DH (74)      | 2.53        | 1.71    | 0.0013          |
|          | Hungarian DH (11)        | 0.14        | 0.01    | 0.4             |
|          | Hungarian non-DH (121)   | 1.01        | 0.28    | 0.13            |
| **C**    | **Psoriasis**            |             |         |                 |
|          | Finnish families (51)    | 1.49        | 0.83    | 0.03            |

Linkage of *IL23R* to celiac disease and psoriasis. Max Z-value, max lod-value and max lod p-value are shown. The number of families informative for linkage is shown in brackets. Linkage to *IL23R* in A) Finnish and Hungarian celiac disease families as well as Finnish and Hungarian celiac disease families combined. B) Finnish and Hungarian celiac disease families with or without dermatitis herpetiformis (DH). C) Finnish psoriasis families.
with controls from [26]; it found no association of the \textit{IL23R} locus with psoriasis (Table 2C, and Additional files 3 and 4). Neither the rs11465804-rs11209026-rs1343151-rs10889677 TGCC risk haplotype (0.164 frequency in cases and 0.165 in controls, \( p = 0.96 \)) nor the rs1343151-rs10889677-rs11209032 TCG protective haplotype (0.537 frequency in cases, 0.549 in controls, \( p = 0.67 \)) were associated with psoriasis in the Finnish case-control material.

**Discussion**

Pathologies that are apparently unrelated have increasingly been shown to share common genetic risk factors, such as celiac disease and schizophrenia in terms of \textit{MYO9B} [37,38]. Conditions that are driven by an overactive/inappropriate immune response can be more easily envisaged to share common factors that contribute to their chronic inflammatory state. It is for this reason that we have examined IBD, psoriasis and celiac disease in this study.

Our study is the first to show genetic association of \textit{IL23R} with IBD in the Swedish population. In particular, we found strong association of the marker rs1004819 with Crohn’s disease, thereby replicating the association reported in the German population [4]. In the German study, association was only demonstrated with this particular SNP, which is located at the junction of two linkage disequilibrium (LD) blocks (Additional file 2). These findings raise the possibility of another polymorphism in the LD block upstream of the rs1004819 marker that affects susceptibility to IBD. Such a polymorphism is envisaged to act independently of rs11209026 or the variants immediately surrounding it.

The risk and protective haplotypes associated with Crohn’s disease and ulcerative colitis in the Swedish population were identical to those found in the first reported association of \textit{IL23R} with IBD [1]. However, \textit{IL23R} was not involved in susceptibility to ulcerative colitis in the Finnish population [26]. These findings are interesting given that the Swedish and Finnish are neighbouring populations and they also share association of Crohn’s disease to the same genetic variants and risk/protective haplotypes at this locus. The differences in Swedish and Finnish cases with ulcerative colitis may reflect genetic variation in the two populations at other IBD risk loci.

The \textit{IL23R} region demonstrated linkage to psoriasis in the Finnish pedigrees, suggesting that the locus is involved in this inflammatory skin disorder. Linkage of this gene region has not previously been shown to psoriasis in the Finnish population. Importantly, in support of our linkage results, association of \textit{IL23R} with psoriasis was confirmed in the Finnish case-controls, demonstrating under-
transmission of previously reported protective variants and over-transmission of the corresponding risk variants. Other studies have reported association to the rs11209026 (Arg381Gln) polymorphism in IL23R, as well as to polymorphisms in IL12B, which encodes the β-chain of the IL23 cytokine [14,15,39]. Taken together, these collective findings suggest that polymorphisms in several components of the IL23/IL23R-pathway may be important for susceptibility to psoriasis. Indeed, anti-IL12/IL23 antibody treatment ameliorates the symptoms of psoriasis [40], further supporting the importance of multiple components this pathway in the disease.

The gene region containing IL23R was strongly linked to celiac disease in the Finnish families, but did not reach statistical significance in the Hungarian pedigrees - a result that perhaps reflects the heterogeneity of the two populations. The discrepancy between the populations could raise questions about the biological relevance of the linkage findings, but large differences in allele and haplotype frequencies between populations have been reported by others, suggesting that the effect of the same genetic risk variant may vary considerably across different populations. Indeed, it is thought that some of the celiac disease risk loci for the Finnish and Hungarian populations are distinct [27]. Therefore, it is possible that the IL23R region is linked to celiac disease in the Finnish population but not the Hungarian. Future replication studies may help to determine whether the region is truly linked to celiac disease.

Interestingly, stratification of the celiac disease dataset by the co-occurrence of dermatitis herpetiformis indicated that linkage was independent of celiac disease sub-phenotype. Despite the linkage results in the Finnish families, the case-control material of all three populations (Finnish, Hungarian and Italian) showed no association of IL23R with celiac disease, and family-based association tests supported the lack of association of these markers.

The linkage of celiac disease to the IL23R region may be due to other genetic factors than the ones reported by Duerr et al. (2006) [1]. In support of this, stratification of the celiac disease dataset by the A-allele of rs11209026 indicated that linkage in the Finnish families with celiac disease was independent of this variant. Intriguingly, this allele A was recently found to be associated with risk instead of protection from both celiac disease and multiple sclerosis in the Spanish population [41]. These findings in the Spanish population suggest that, if rs11209026 is the primary functional variant, IL23R would play an opposite role in celiac disease and multiple sclerosis compared to IBD and psoriasis. Perhaps more likely, is that these opposite alleles are simply tagging distinct haplotypes carrying the real primary risk variants.

Variants in the LD block upstream of IL23R or in the downstream LD block covering IL12RB2, may explain the linkage to celiac disease in the Finnish population. IL12RB2 and IL12RB1 encode for the two chains of the IL12 receptor. The IL23 receptor shares the protein encoded by IL12RB1 but also requires IL23R. Similarly, the ligands bound by these receptors, IL12 and IL23, are composed by shared subunits: IL12 is encoded by IL12A and IL12B, while IL23 is encoded by IL23A and IL23B. Interestingly, celiac disease is associated with IL12A [42,43] and thereby differs from IBD and psoriasis, where IL12B variants have shown risk effect. Hence, the IL12A association and the proximity of IL12RB2 to IL23R (which appears linked to celiac disease), suggest that the genes of the IL12 pathway are particularly interesting to investigate in future genetic studies of celiac disease. Independent associations of psoriasis and psoriatic arthritis with both IL23R and a SNP 4 kb upstream of IL12RB2 [39], indicate that extended studies in this gene cluster would be relevant to other chronic inflammatory diseases as well.

IL23R gene variants have now been repeatedly implicated in a number of inflammatory diseases and perhaps suggest that these pathologies are mediated by the Th17 pathway. Despite many studies finding association of these diseases with the IL23R region, few have reported functional evidence for the involvement of IL23R variants. It is known that the rs11209026 SNP results in an amino acid change in the intracellular domain of the IL23 receptor and thus the polymorphism may affect the downstream signalling of the receptor. However, our preliminary functional studies suggest that the rs11209026 genotype does not significantly affect expression of the IL23 receptor on peripheral blood mononuclear cells of healthy donors (data not shown). Nevertheless, it cannot be excluded that other factors carried on the protective haplotype tagged by rs11209026 could have an effect on expression levels of IL23R, or on the stability or alternative splicing of mRNA.

It is apparent that the variants in the IL23R region examined in this study are not associated with celiac disease. However, it is equally clear that some factor in this gene region affects susceptibility to celiac disease. The region needs to be investigated further to identify the precise genetic variants that contribute to celiac disease. Future studies employing a tagging strategy of the whole IL12RB2 gene may be useful in IBD, psoriasis and celiac disease. Such a strategy may be able to elucidate the disease-causing variants in celiac disease, as well as identifying additional variants that modify the risk of IBD and psoriasis.

Conclusion
Our study is the first to report association of IL23R with Crohn’s disease and ulcerative colitis in Swedish patients with IBD. It is also the first study to demonstrate linkage.
and association of the IL23R region with psoriasis in the Finnish population. But perhaps the most interesting novel finding is that of linkage of the IL23R region to celiac disease. It remains to be elucidated whether IL23R, IL12RB2 or another gene at 1p31 confers risk to celiac disease.

**Competing interests**
The authors declare that they have no competing interests.

**Authors’ contributions**
EE performed the genetic studies and wrote the manuscript. IK performed the IL23R protein analysis. KKAinu, SS, and US-K contributed to diagnosis and identification of psoriasis samples. ML performed genetic analysis on the Finnish IBD samples. FZ, TN, SV, and AV contributed to the diagnosis and identification of the Italian celiac disease samples. RA, ZP, and GS contributed to diagnosis and identification of the Italian celiac disease samples. MF, KKurppa, KKaukinen, and MM contributed to diagnosis and identification of Hungarian celiac disease samples and controls. Kkurppa, KKaukinen, and MM contributed to diagnosis and identification of Finnish celiac disease samples. RA, ZP, and GS contributed to diagnosis and identification of Finnish IBD samples. RL, LT, FB, JH, and MD’A contributed to diagnosis and identification of Swedish IBD disease samples. MM, KKontula, US-K, JK and PS participated in the design and coordination of the study, and PS, MD’A and KKontula funded it. PS and MD’A conceived of the study and participated in writing the manuscript. All authors read and approved of the final manuscript.

**Acknowledgements**
All the study subjects are warmly thanked for their participation in the study and we thank Hanne Ahola and Anne Heimonen for their excellent technical assistance, as well as Kristina Duvefelt for supervising genotyping work. We thank Erzsébet Szathmári, Judit B. Kovács, Margit Lórszcz and Anikó Nagy for their work with the Hungarian families. Andrea de Kauwe is thanked for critical reading of the manuscript.

This work and the study groups have been funded by the EU Commission through a Marie Curie Excellence Grant (FP6 contract MEXT-CT-2005-025270), the Academy of Finland, the Hungarian Scientific Research Fund (contract OTKA 61886), the Swedish Research Council, the University of Helsinki Funds, Biocentrum Helsinki, the Research Fund of Tampere University Hospital, the Competitive Research Funding of the Pirkanmaa Hospital District, the Special State Funds of the Helsinki University Central Hospital (EVO), the Yrjö Jahnsson Foundation, the Foundation of Pediatric Research, the Sigrid Juselius Foundation, the Finnish Cultural Foundation, the Paulus Kuistila Memorial Foundation, the Finnish Society for Gastroenterological Research, and the Finnish Celiac Disease Society.

**References**
1. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhardt AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barnada MM, Rotter JI, Nicolae DL, Cho JH: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314(5804):1461-1463.
2. Brown SJ, Mayer L: The immune response in inflammatory bowel disease. Am J Gastroenterol 2007, 102(9):2058-2069.
3. Oliver J, Rueda B, Lopez-Navot MA, Gomez-Garcia M, Martin J: Replication of an association between IL23R gene polymorphism with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007, 5(8):977-81. 981.e1–2.
4. Glas J, Seidler J, Wetzke M, Konrad A, Torok HP, Schmechel S, Tonolenci L, Grassl C, Dambacher J, Pfennig S, Maijer K, Griga T, Klein W, Epplein JT, Scheinmann L, Wolczyk C, RP, Gwede C, QM, sinkuhen T, Muller-Myllykukko B, Wolczany J, Henss J, Matussek T, Brand S. rs1004819 is the main disease-associated IL23R variant in German Crohn's disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. PLoS ONE 2009, 4(9):e69818.

5. Raelson JV, Little RD, Ruether A, Fournier H, Paquin B, Van Eerdeewegh P, Bradley WE, Croteau P, Nguyen-Huu Q, Segal J, Debrus S, Allard R, Rosenstein P, Franke A, Jacobs G, Nikolaus S, Vidal JM, Szego P, Laplante N, Clark HF, Paulussen RJ, Hooper JW, Keith TP, Beloucet A, Schreiber S. Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci. Proc Natl Acad Sci USA 2007, 104(37):14747-14752.

6. Tremelling M, Cummings F, Fisher SA, Mansfield J, Gwilliam R, Keniry A, Vickers K, McAllister LB, Hansen CB, Papenfuß J, Prescott SM, White TJ, Leppla S, Mathew CG, Parkes M, Satsangi J. IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology 2007, 132(5):1653-1661.

7. Roberts RL, Geary RB, Hollis-Moffatt JE, Miller AL, Reid J, Abkevich V, Timms KM, Gut A, Lanchbury JS, Merriman TR, Barclay ML, Kennedy MA. IL23R R381Q and ATG16L1 T302A are strongly associated with Crohn's disease in a study of New Zealand Caucasian inflammatory bowel disease. Am J Gastroenterol 2007, 102(12):2754-2761.

8. Taylor KD, Targan SR, Mei I, Ippoliti AF, McGovern D, Mengesha E, King L, Rotter JI. IL23R haplotypes provide a large population attributable risk for Crohn's disease. Inflamm Bowel Dis 2008, 14(9):1185-1191.

9. Marquez A, Mendoza JL, Taxonera C, Díaz-Rubio M, De la Concha EG, Urcelay E, Martinez A. IL23R and IL12B polymorphisms in Spanish IBD patients: No evidence of interaction. Inflamm Bowel Dis 2008, 14(9):192-199.

10. Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, Prescott NJ, Nimmo ER, Massey D, Berzuini C, Johnson C, Barrett JC, Cummings FR, Drummond H, Lees CW, ONnie CM, Hansen CE, Chalazonitis K, Inouye M, Ewels P, Ravindrarajah R, Keniry A, Hunt S, Gwilliam R, Wu S, Owadally W, Lewis CM, Yin J, Sa L, Wellcome Trust Case Control Consortium, Lobo A, Forbes A, Sanderson J, Benedict F, Berzuini C, Forbes A, Lewis CM, Cardon L, Deloukas P, Jewell D, Mathew CG, Parkes M, Satsangi J. IL23R variants determine susceptibility to Crohn's disease. Nature 2007, 449(7161):668-672.

11. Dubinsky MC, Wang D, Picornell Y, Wrobel I, Katzir L, Quiros A, Dubinsky MC, Wang D, Picornell Y, Wrobel I, Katzir L, Quiros A, McAllister LB, Hansen CB, Papenfuß J, Prescott SM, White TJ, Leppla S, Mathew CG, Parkes M, Satsangi J. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet 2008, 40(7):1173-1174.

12. Baldassano RN, Bradfield JP, Micos DS, Kim CE, Glessner JT, Casale TB, Martinez Jr, Hohman MR, Mathew CG, Parkes M, Satsangi J. IL23R haplotypes provide a large population attributable risk for Crohn's disease. Inflamm Bowel Dis 2008, 14(9):1185-1191.

13. Van Limbergen J, Russell RK, Nimmo ER, Drummond HE, Smith L, Van der Auwera C, Devin P, Surakka I, Ninni-Levi A, Balsamo G, Huh K, McInnes IB, Oppermann U, Adelskog L, Lernmark A, Holmdahl R, Bruce IN, McDonald D, Ferreira T, Pereira-Gale J, Hallgrimsdottir IB, Howie BN, Marchini JL, Worthington J, Barrett JC, Bishop TD, Iles MM, Macauley A, Udaløsaga N, Hall AS, (Leicester), Braun PS, Burton PR, Dixon RJ, Mangino M, Stevens S, Tobin MD, Thompson JR, Samani NJ, Crohn's Disease (Cambridge), Bredin F, Tremelling M, Parkes M, (Edinburgh), Drummond H, Lees CW, Nimmo ER, Newport H, Sinicrope F, Oxford, Forbes A, Lewis CM, ONnie CM, Prescott NJ, Sanderson J, Matthew CG, (Newcastle). Gut 2007, 56(8):1173-1174.

14. Capon P, Di Meglio P, Szaub J, Prescott NJ, Dunster C, Baumber L, Timms K, Gut A, Abkevich V, Burden AD, Lanchbury J, Barker JN, Trembath RC, Nisbet FG. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007, 122(2):201-206.

15. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callus KP, Matsunami N, Ardill KG, Civello D, Catanese J, Leong DU, Pankow JM, McAllister LB, Hansen CB, Papenfuss J, Prescott SM, White TJ, Leppert MF, Krueger GG, Begovich AB. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007, 80(2):273-290.
